Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Perrigo Company plc

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving landscape of biotechnology and pharmaceuticals, understanding financial health is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of CRISPR Therapeutics AG and Perrigo Company plc from 2014 to 2023. Over this period, CRISPR Therapeutics AG, a pioneer in gene-editing technology, saw its SG&A expenses grow by over 1,400%, reflecting its rapid expansion and increased operational activities. In contrast, Perrigo Company plc, a stalwart in the pharmaceutical industry, maintained a relatively stable SG&A expense profile, with a modest increase of about 89% over the same period. This stability underscores Perrigo's established market presence and operational efficiency. The data highlights the dynamic nature of the biotech sector, where emerging companies like CRISPR Therapeutics AG are scaling rapidly, while established players like Perrigo continue to optimize their operations.